As demand for CAR T therapies grows, modular platforms are offering process development teams new ways to improve cell expansion, recovery and scale-up. Chimeric antigen receptor (CAR) T cell ...
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
The remarkable clinical success of CAR T therapies in blood cancers has validated the promise of engineered cell therapies. But according to Adam Janvier, PhD, head of cell therapy at eXmoor Pharma, ...
For decades, advanced medical breakthroughs have followed a familiar pattern: scientific discovery, clinical promise, followed at length by broad patient access–if it comes at all. Cancer treatments ...
Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...
ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor inhibition where conventional immunotherapy fails. (Nanowerk Spotlight) ...
Immune cells that are engineered to attack cancer cells, known as CAR-T cells, are used to treat some types of blood cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results